| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cichoric acid Cichoric acid / Chicoric acid — Cichoric acid is a naturally occurring dicaffeoyltartaric acid polyphenol, formally a hydroxycinnamic acid derivative composed of two caffeic acid units esterified to tartaric acid. It is best classified as a plant-derived phenolic acid / caffeic-acid derivative rather than a drug. Standard abbreviations include Cic, ChicA, and CA, although CA is ambiguous because it is also used for caffeic acid, chlorogenic acid, carnosic acid, and many other database entries. Major sources include Echinacea purpurea, chicory, lettuce, basil, dandelion, and other Asteraceae/Lamiaceae plants. It is commonly used as a quality-marker compound for Echinacea purpurea extracts, but its direct cancer-development status remains preclinical only. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral systemic translation is constrained by polyphenol-type absorption, metabolism, plasma protein binding, and formulation stability. Rat PK/tissue-distribution work exists, but direct human PK data for isolated cichoric acid are limited. Echinacea extract exposure cannot be assumed to equal isolated cichoric acid exposure because alkamides, polysaccharides, glycoproteins, caftaric acid, and other constituents may drive part of the immune effect. In-vitro vs systemic exposure relevance: Many mechanistic studies use low-to-high micromolar cichoric acid concentrations. These concentrations may exceed free systemic exposure achievable from ordinary oral Echinacea or food intake, especially after first-pass and microbial metabolism. Low-micromolar effects such as 5 μM otoprotection in zebrafish are more pharmacologically plausible than high-micromolar cytotoxicity screens, but human-equivalent exposure remains uncertain. Clinical evidence status: Cancer: preclinical only; no adequate human cancer trials for isolated cichoric acid. Immune / respiratory use: human evidence exists for Echinacea preparations, but not as isolated cichoric acid attribution. Alzheimer’s disease: preclinical only, with cell and animal-model support but no validated human clinical efficacy. Regulatory/deployment status: listed as a natural-health-product ingredient name by Health Canada; not an approved anticancer or AD therapeutic. Cichoric Acid Mechanistic Profile
TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr Alzheimer’s disease relevance: Cichoric acid has meaningful AD-preclinical relevance but no validated human AD clinical evidence. The main AD rationale is neuroinflammation and amyloid-pathology modulation rather than direct symptomatic cholinergic therapy. In animal and cellular AD models, cichoric acid has been reported to reduce Aβ burden, lower APP/BACE1 markers, improve synaptic-function markers, and activate antioxidant signaling. This supports an AD database sub-entry as preclinical / experimental, not as a clinically established intervention. AD mechanisms (ranked):
Clinical evidence status: AD evidence remains preclinical. No adequate human RCT evidence supports cichoric acid as an Alzheimer’s disease treatment. Translation constraints include oral exposure, blood-brain exposure, dose standardization, and uncertainty over whether whole-plant extracts reproduce isolated cichoric acid effects. Cichoric Acid Alzheimer’s Disease Mechanistic Profile
TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a type of nuclear receptor that plays a crucial role in regulating various biological processes, including glucose metabolism, lipid metabolism, and inflammation. It is primarily expressed in adipose tissue, but it is also found in other tissues, including the colon, breast, and prostate. PPAR-γ has been shown to have both tumor-suppressive and tumor-promoting effects, depending on the type of cancer and the context. In some cancers, activation of PPAR-γ can inhibit cell proliferation and induce apoptosis, while in others, it may promote tumor growth. PPARγ – Plays a central role in adipogenesis, lipid storage, and insulin sensitivity. – Widely expressed in adipose tissue, but also present in colon, breast, and immune cells. – In addition to metabolic functions, PPARγ regulates cell differentiation, apoptosis, and has anti-inflammatory effects. – Ligand binding (such as endogenous fatty acids or synthetic agonists like thiazolidinediones) alters transcriptional programs impacting cell cycle and survival. – In many cases, PPARγ is expressed in tumor cells, and its activation has been linked to induction of differentiation and growth arrest. – However, expression levels can differ based on tumor subtype, with some studies reporting elevated levels while others note reductions in aggressive tumors. – Crosstalk with other signaling pathways (e.g., Wnt/β-catenin, MAPK) can alter PPARγ's net effect in cancer cells. |
| 6623- | Cic, | MTX, | Chicoric acid prevents methotrexate hepatotoxicity via attenuation of oxidative stress and inflammation and up-regulation of PPARγ and Nrf2/HO-1 signaling |
| - | in-vivo, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:416 Target#:259 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid